A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase ...
(Reuters) - Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current ...
EAST HANOVER, N.J., Nov. 1, 2021 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Scemblix ® (asciminib) for the treatment of chronic myeloid leukemia ...
Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...
EAST HANOVER, N.J., June 7, 2022 /PRNewswire/ -- Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid ...
-- Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation rate due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback